Related Resources for this page:
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- ResearchADCs
- Oncogenic BRAF in cancer
- ResearchCancerImmunotherapy
- ResearchHERPathways
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- ResearchVEGF
- Clinical Trials
- Cancer Biomarkers
- Ovarian Cancer
- Receptor-Mediated Endocytosis
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- Oncogenic BRAF in cancer
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- VEGF in ovarian cancer
- VEGF as a prognostic factor in ovarian cancer
- Summary
- Ovarian Cancer
- Future Directions
- Antibody-Drug conjugates
- HER Signaling
- Receptor-Mediated Endocytosis
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- Emerging therapeutic options
- Emerging therapeutic options
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- HER Signaling
- Anti-HER3/EGFR MAb (MEHD7945A)
- Emerging therapeutic options
- Emerging therapeutic options
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Non-Antibody Biologics
- Apoptosis
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Targeted Small Molecules
- Apoptosis
- MAPK Signaling
- PI3K/Akt/mTOR Signaling
- Anti-HER3/EGFR MAb (MEHD7945A)
- Glossary
- Resisting apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Slide decks and videos
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Melanoma
- Multiple Myeloma
- Traditional Monoclonal Antibodies
- Angiogenic Signaling
- B-cell Surface Proteins
- HER Signaling
- Parsatuzumab (Anti-EGFL7)
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- Emerging therapeutic options
- Emerging therapeutic options
- Inhibition of HER2 dimerization
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Glossary
- Slide decks and videos
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Melanoma
- Antibody-Drug conjugates
Ovarian Cancer
Disease Information
Genentech BioOncology is dedicated to advancing the science of ovarian cancer therapy through comprehensive research and education. Ovarian cancer is a malignancy that initiates in the ovaries.1 Based on the source of origin, ovarian tumors are classified into 3 different categories.2
Epithelial ovarian tumors
Most ovarian tumors are of epithelial origin and arise from cells that cover the outer surface of the ovary.2 Ovarian tumors may be benign or malignant in clinical behavior.2 Benign epithelial tumors do not spread to distant organs and therefore do not usually cause serious illness.2 A number of benign epithelial tumors have been identified that include serous adenomas, mucinous adenomas, and Brenner tumors.2
Malignant epithelial cancers, referred to as carcinomas, constitute ≈85% to ≈90% of epithelial ovarian cancers.2
- Based on their unique morphologic features, malignant epithelial ovarian carcinoma tumors may be classified into serous, mucinous, endometrioid, and clear cell subtypes. If the tumor cells do not exhibit any of the 4 morphologic types, they are classified as undifferentiated types; these tumors typically grow and spread more quickly than their differentiated counterparts2
- Malignant ovarian epithelial tumors may also include 2 rare subtypes, namely, primary peritoneal carcinoma and fallopian tube cancers.2 The latter tumor subtype has a marginally better prognosis than other ovarian cancers2
- Ovarian cancers may sometimes include slow-growing tumors of low malignant potential, referred to as borderline epithelial ovarian cancers.2 These tumors are less life-threatening than most ovarian cancers and tend to affect women at a younger age2
Ovarian germ cell tumors
Ovarian germ cell tumors typically originate from germ cells that produce the eggs and account for less than 2% of all ovarian cancers.2 Most ovarian germ cell tumors are considered benign in nature and are associated with a good prognosis; studies reveal that 90% of patients afflicted with ovarian germ cell tumors survive at least 5 years after initial diagnosis.2 Depending upon the morphologic features, ovarian germ cell tumors may be grouped into 5 major categories, namely teratoma, dysgerminoma, endodermal sinus tumor, and choriocarcinoma.2
Ovarian stromal cell tumors
About 1% of ovarian cancers are designated as ovarian stromal cell tumors.2 The majority of the stromal tumors are found in women older than 50, with only ≈5% of stromal tumors reported in young girls.2 These tumors typically originate from stromal tissue and produce the female hormones estrogen and progesterone.2 Based on morphologic features, malignant stromal tumors may be divided into granulosa cell tumors (the most common type), granulosa-theca tumors, and Sertoli-Leydig cell tumors.2
Ovarian Cancer Demographic Statistics
- Ovarian cancer ranks second among gynecologic cancers, accounting for an estimated 21,880 new cases in 2010 in the United States3
- More deaths result from ovarian cancer than any other malignancy affecting the female reproductive system, accounting for an estimated 13,850 deaths in 2010 in the United States2
Ovarian Cancer Epidemiology
- New studies indicate that mutations in BRCA1 and BRCA2 genes may increase ovarian cancer risk2
- Other risk factors associated with ovarian cancer include family history of breast and ovarian cancers, estrogen and hormonal therapies, age, obesity, and the use of certain fertility drugs2
Other links to ovarian cancer disease information
These links give a sampling of other sites offering information on ovarian cancer, which you may find useful in your practice.
- National Cancer Institute at National Institutes of Health, Ovarian Cancer
- ASCO Cancer Portals - Gynecologic Cancers
- Cancer Facts & Figures
Unless otherwise indicated, Genentech, Inc. is neither affiliated with nor endorses any of the organizations listed.
References:
- 1.
- US Department of Health and Human Services. National Cancer Institute. What you need to know about™ ovarian cancer. www.cancer.gov/cancertopics/wyntk/ovary/wyntk_ovarian.pdf. Accessed April 14, 2011.
- 2.
- American Cancer Society. Ovarian cancer. www.cancer.org/acs/groups/cid/documents/webcontent/003130-pdf.pdf. Accessed April 14, 2011.
- 3.
- American Cancer Society. Cancer Facts & Figures 2010. www.cancer.org/acs/groups/content/
@epidemiologysurveilance/documents/document/acspc-026238.pdf. Accessed April 14, 2011.